CDP1
mAbexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT04508829)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05215925 | Phase 2 | Feb 1, 2023 | Shanghai Henlius Biotech |
| NCT04151810 | Phase 1 | Dec 30, 2019 | Guilin Sanjin, Sichuan University |
| NCT03881787 | Phase 1 | Feb 27, 2019 | Fudan University, Guilin Sanjin, Sichuan University |
| NCT03744208 | Phase 2 | Dec 30, 2018 | Chinese Academy of Medical Sciences |
| NCT03713372 | Phase 2 | Nov 30, 2018 | Chinese Academy of Medical Sciences, Sinocelltech Ltd. |
| NCT03491709 | Phase 1 | Jun 1, 2018 | Guilin Sanjin, Huazhong University of Science and Technology |
| NCT04508829 | Phase 2 | Jan 1, 2016 | Fudan University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guilin Sanjin | For profit | 3 | 3 | 1 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 1 | 1 | 2018 |
| Fudan University | Academic/Hospital | 2 | 1 | 2 | 2016 |
| Sichuan University | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Shanghai Henlius Biotech | For profit | 1 | 1 | 1 | 2023 |
| Sinocelltech Ltd. | For profit | 1 | 1 | 1 | 2018 |
7 organizations
Page 1 / 1